UBX1325 reached a controlled human trial before UNITY stopped operating. UNITY's current website says the company is no longer operating. This record therefore treats UNITY's development programme as discontinued. Any transfer of the asset would require a new, identifiable development record.
The drug was designed to remove senescent cells in diseased retinal tissue. UNITY investigated whether this could improve vision in people whose diabetic macular oedema had responded poorly to previous anti-VEGF treatment.
ASPIRE failed its primary comparison based on the average of weeks 20 and 24. The company reported non-inferiority to aflibercept at week 36. Selecting only the later time point leaves out the trial's prespecified test.
- Inhibit BCL-xLA cell-survival pathway targeted by the programme.
- Test effects in retinal tissueLocal delivery defines the experimental setting.
- Observe clinical outcomesThe trial results determine the treatment claim.
A proposed mechanism does not override a disappointing clinical result. Sources for this account.
The mechanism
UBX1325 inhibits BCL-xL, a protein involved in keeping cells alive. Senescent cells can depend on survival pathways that protect them from apoptosis, the regulated process of cell death. The proposed approach was to disable a survival pathway in the diseased tissue.
UNITY's earlier laboratory experiments used human cell cultures and mouse retinal disease models. Its filings described the active parent molecule UBX0601, released from the phosphate prodrug UBX1325. The company reported reduced survival of senescent cells in culture and changes in retinal disease measures in mice.
Local delivery through an injection into the eye defined the programme's scope. Those experiments do not establish that the same compound, exposure or therapeutic window would work across other tissues. A retinal programme can answer a retinal question while leaving systemic senolytic development unresolved.
Human evidence
ASPIRE enrolled 52 people and compared repeat UBX1325 injections with aflibercept in a randomised, double-masked study. The comparator already treated the underlying eye disease. This was a demanding test of comparative performance, with vision measured through best-corrected visual acuity.
The sponsor reported a favourable subgroup result in participants with lower central subfield thickness. A confirmatory trial would need to test whether this identifies a reliably responsive population.
The June 2025 SEC filing records the closing out of ASPIRE, officer departures and a planned dissolution.
Studies and experimental evidence
ASPIRE Phase 2b
- Design
- Randomised, double-masked, active-controlled
- Population or model
- Previously treated adults with diabetic macular oedema
- Sample size
- 52
- Comparison
- Aflibercept
- Duration
- 36-week results
- Outcome
- Best-corrected visual acuity; primary comparison averaged weeks 20 and 24
Primary non-inferiority comparison missed; company reported non-inferiority at week 36
Small study; results cited here are sponsor disclosure, with subgroup interpretation unresolved
Funding and interests: UNITY sponsored
Preclinical UBX1325 / UBX0601 experiments
- Design
- Cell assays and mouse retinal disease models
- Population or model
- Human cell cultures and mice
- Sample size
- Multiple experiments; no single pooled sample
- Comparison
- Non-senescent cells or vehicle controls, depending on experiment
- Duration
- Varied by experiment
- Outcome
- Cell survival, retinal leakage and retinal function
Company filings report senolytic activity and retinal changes
Sponsor-reported preclinical evidence; species and model limits
Funding and interests: UNITY
Development history
Human testing began
UNITY's annual filing records the start of the first human study.
Complete ASPIRE results disclosed
Week-36 findings were reported alongside the missed primary time-window comparison and strategic review.
Operating programme wound down
The board approved seeking dissolution and the company closed out ASPIRE.
Unresolved questions
- Did UBX1325 remove senescent cells in human retinal tissue, and how directly was that demonstrated?
- Would an independently designed trial reproduce the lower-thickness subgroup finding?
- What explains the difference between the primary time-window comparison and the week-36 comparison?
- Has another developer acquired the asset and publicly committed to a new study?
UNITY's closure leaves the programme's future unresolved. An asset transfer would need a named sponsor, protocol and study registration to establish resumed development. An archived registry entry alone cannot establish that work has restarted.
Sources
- Company disclosure · 5 May 2025Complete 36-week ASPIRE results and corporate update
Sponsor results, comparator, sample and endpoint.
Checked 4 Oct 2026 - Company disclosure · 30 Jun 2025UNITY Form 8-K: wind down and planned dissolution
Records ASPIRE closeout and operational change.
Checked 4 Oct 2026 - Company disclosure · UndatedUNITY Biotechnology current website
States the company no longer operates.
Checked 4 Oct 2026 - Company disclosure · 2025UNITY 2024 annual report
Historical clinical programme and mechanism.
Checked 4 Oct 2026 - Company disclosure · 2021UNITY 2020 annual report: preclinical pharmacology
Describes assays, prodrug and retinal models.
Checked 4 Oct 2026 - Trial registry · UndatedASPIRE study record NCT06011798
Trial registry identifier. The status account above relies on the dated sponsor disclosures; a current detailed registry status was not established.
Checked 4 Oct 2026
Dr T Smith, organic chemist and science educator. Review date: 4 Oct 2026. Report a correction.